Your browser is no longer supported. Please, upgrade your browser.
DFFN Diffusion Pharmaceuticals Inc. monthly Stock Chart
DFFN [NASD]
Diffusion Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.56 Insider Own0.23% Shs Outstand59.63M Perf Week-4.35%
Market Cap66.80M Forward P/E- EPS next Y-11.62 Insider Trans0.00% Shs Float45.86M Perf Month32.53%
Income-11.60M PEG- EPS next Q-0.06 Inst Own8.60% Short Float1.20% Perf Quarter80.39%
Sales- P/S- EPS this Y78.90% Inst Trans1.06% Short Ratio0.09 Perf Half Y149.43%
Book/sh0.52 P/B2.12 EPS next Y-4741.70% ROA-57.80% Target Price- Perf Year-49.31%
Cash/sh0.18 P/C6.19 EPS next 5Y- ROE-68.60% 52W Range0.21 - 2.42 Perf YTD138.77%
Dividend- P/FCF- EPS past 5Y58.90% ROI- 52W High-54.55% Beta1.36
Dividend %- Quick Ratio9.10 Sales past 5Y- Gross Margin- 52W Low421.33% ATR0.12
Employees10 Current Ratio9.10 Sales Q/Q- Oper. Margin- RSI (14)47.85 Volatility8.26% 12.98%
OptionableNo Debt/Eq0.00 EPS Q/Q90.90% Profit Margin- Rel Volume0.28 Prev Close1.12
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume5.87M Price1.10
Recom- SMA20-5.30% SMA501.25% SMA20067.28% Volume1,688,829 Change-1.79%
Mar-21-18Initiated H.C. Wainwright Buy $1.25
Jul-27-20 08:00AM  
Jul-07-20 08:00AM  
Jul-06-20 07:47PM  
Jun-11-20 08:00AM  
Jun-01-20 08:00AM  
May-26-20 08:00AM  
May-20-20 01:00PM  
08:00AM  
May-19-20 03:18PM  
09:05AM  
May-18-20 09:05AM  
May-11-20 04:11PM  
May-05-20 08:00AM  
Apr-27-20 08:00AM  
Apr-03-20 07:30AM  
Apr-01-20 08:00AM  
Mar-24-20 04:05PM  
Mar-19-20 07:28AM  
Mar-18-20 06:35PM  
Mar-17-20 04:10PM  
Mar-12-20 08:00AM  
Feb-07-20 08:30AM  
Jan-10-20 08:00AM  
Dec-30-19 08:00AM  
Dec-22-19 06:43PM  
Dec-13-19 02:07PM  
Dec-12-19 09:55AM  
08:00AM  
Dec-11-19 07:21AM  
Dec-10-19 04:00PM  
Nov-20-19 07:25AM  
Nov-19-19 04:05PM  
Nov-15-19 11:43AM  
Nov-13-19 09:34AM  
Nov-11-19 08:00AM  
Oct-17-19 08:30AM  
Sep-19-19 11:07AM  
Sep-03-19 10:30AM  
Aug-15-19 10:15AM  
Aug-08-19 05:15PM  
Jul-23-19 08:30AM  
Jul-11-19 03:21PM  
May-28-19 04:05PM  
May-24-19 09:00AM  
May-23-19 07:30AM  
May-13-19 02:45PM  
May-09-19 04:05PM  
Apr-17-19 10:00AM  
Mar-20-19 09:00AM  
Mar-08-19 05:08PM  
Feb-11-19 04:00PM  
Jan-22-19 01:55PM  
Jan-04-19 09:00AM  
Jan-03-19 09:00AM  
Dec-18-18 06:55AM  
Dec-17-18 01:30PM  
09:55AM  
Dec-13-18 02:00PM  
Dec-10-18 10:15AM  
Nov-15-18 09:15AM  
Nov-14-18 09:00AM  
Oct-15-18 12:00PM  
Sep-25-18 09:00AM  
Sep-12-18 09:00AM  
Aug-29-18 08:00AM  
Aug-16-18 02:00PM  
Aug-13-18 08:30AM  
Jun-12-18 08:30AM  
May-29-18 01:04PM  
May-15-18 04:45PM  
May-10-18 04:05PM  
Apr-19-18 04:45PM  
Apr-03-18 04:00PM  
07:30AM  
Feb-22-18 10:00AM  
Feb-06-18 04:00PM  
Feb-01-18 08:15AM  
Jan-29-18 04:00PM  
Jan-24-18 07:30AM  
Jan-18-18 01:54PM  
06:00AM  
Jan-10-18 08:00AM  
Jan-03-18 08:00AM  
Jan-02-18 04:09PM  
Dec-27-17 08:00AM  
Dec-19-17 01:35PM  
Dec-08-17 12:43PM  
Nov-20-17 08:00AM  
Nov-16-17 02:00PM  
Nov-13-17 08:00AM  
Oct-18-17 08:20AM  
Oct-17-17 10:28AM  
07:30AM  
Oct-10-17 10:00AM  
Sep-13-17 07:49PM  
Sep-05-17 11:11AM  
Aug-31-17 11:00AM  
Aug-23-17 07:30AM  
Aug-14-17 04:01PM  
Jul-31-17 08:30AM  
Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.